Koite Health develops Lumoral, described in its materials as the world's first targeted antibacterial treatment for home use, focused on improving global oral health care. The company has launched Lumoral in several European markets, including Germany, Italy, Great Britain and Denmark, and continues to open new markets. Koite has sold more than 20,000 Lumoral devices and reported over 1,000,000 treatments delivered. The company managed to double its revenues in 2023. Funds raised in the autumn 2023 share issue will be used to support international growth of Lumoral and to develop new applications. Founded in 2018 and based in Espoo, Finland, Koite aims to expand internationally and broaden its investor base.

Total raised

$4M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2024